NIBIB-funded researchers are developing an implantable, biodegradable film that helps to regenerate the native cartilage at the site of damage. Their study, performed in rabbits, could be an initial, important step in the establishment of a new treatment for this common condition, osteoarthritis.
The FDA approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata. The action marks the first FDA approval of a systemic treatment (i.e. treats the entire body rather than a specific location) for alopecia areata.
Background The Health Disparities in Osteoarthritis (OA) workshop brought together OA investigators with others who have expertise in health disparities to exchange ideas regarding how/why disparities in OA treatment and care exist and how they can be addressed. Panelists and speakers highlighted mechanisms through which behavioral and biomedical science integration can lead to better health in OA. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Aging (NIA), and National Institute on Minority Health and Health Disparities (NIMHD) sponsored the workshop. It was organized by NIH staff and meeting co-chairs Drs. Arleen F. Brown (University